Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its target price lifted by Royal Bank Of Canada from $133.00 to $140.00 in a report issued on Wednesday, MarketBeat reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

ZBH has been the subject of several other reports. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a hold rating to a sell rating in a report on Thursday, April 13th. Goldman Sachs Group, Inc. (The) started coverage on shares of Zimmer Biomet Holdings in a report on Tuesday, May 16th. They set a sell rating and a $92.00 price target for the company. Canaccord Genuity restated a buy rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Wells Fargo & Company cut shares of Zimmer Biomet Holdings from an outperform rating to a market perform rating in a report on Friday, April 28th. Finally, Oppenheimer Holdings, Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the stock a buy rating in a report on Friday, April 28th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings currently has an average rating of Buy and a consensus price target of $137.00.

Shares of Zimmer Biomet Holdings (NYSE ZBH) traded down 0.09% during trading on Wednesday, reaching $128.97. 253,932 shares of the company traded hands. The firm has a market capitalization of $26.01 billion, a PE ratio of 52.79 and a beta of 1.23. Zimmer Biomet Holdings has a 12 month low of $95.63 and a 12 month high of $133.21. The firm has a 50-day moving average price of $121.37 and a 200-day moving average price of $116.68.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 EPS for the quarter, topping the consensus estimate of $2.11 by $0.02. The business had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $2.00 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings will post $8.54 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Royal Bank Of Canada Boosts Zimmer Biomet Holdings, Inc. (ZBH) Price Target to $140.00” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/06/26/royal-bank-of-canada-boosts-zimmer-biomet-holdings-inc-zbh-price-target-to-140-00.html.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is 39.67%.

In other news, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $116.76, for a total value of $723,912.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. In the last three months, insiders sold 111,262 shares of company stock worth $13,103,927. Insiders own 1.07% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Alpha Windward LLC raised its position in Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares in the last quarter. Sandy Spring Bank raised its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Cleararc Capital Inc. raised its position in Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares in the last quarter. Finally, Enterprise Financial Services Corp raised its position in Zimmer Biomet Holdings by 1.0% in the first quarter. Enterprise Financial Services Corp now owns 2,637 shares of the medical equipment provider’s stock worth $322,000 after buying an additional 27 shares in the last quarter. 84.34% of the stock is currently owned by institutional investors.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.